AU7471096A - Compositions and methods for treating bone deficit conditions - Google Patents

Compositions and methods for treating bone deficit conditions

Info

Publication number
AU7471096A
AU7471096A AU74710/96A AU7471096A AU7471096A AU 7471096 A AU7471096 A AU 7471096A AU 74710/96 A AU74710/96 A AU 74710/96A AU 7471096 A AU7471096 A AU 7471096A AU 7471096 A AU7471096 A AU 7471096A
Authority
AU
Australia
Prior art keywords
compositions
methods
treating bone
deficit conditions
bone deficit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU74710/96A
Other versions
AU706262B2 (en
Inventor
Nand Baindur
Scott M. Harris
Laurence H. Hurley
Sean M. Kerwin
Maria Kontoyianni
Gregory R Mundy
Mark W. Orme
Charles Petrie
Kirk G. Robbins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
OsteoScreen Inc
University of Texas at Austin
Original Assignee
Zymogenetics Inc
OsteoScreen Inc
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc, OsteoScreen Inc, University of Texas at Austin filed Critical Zymogenetics Inc
Publication of AU7471096A publication Critical patent/AU7471096A/en
Application granted granted Critical
Publication of AU706262B2 publication Critical patent/AU706262B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU74710/96A 1995-10-23 1996-10-23 Compositions and methods for treating bone deficit conditions Ceased AU706262B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US583095P 1995-10-23 1995-10-23
US60/005830 1995-10-23
PCT/US1996/017019 WO1997015308A1 (en) 1995-10-23 1996-10-23 Compositions and methods for treating bone deficit conditions

Publications (2)

Publication Number Publication Date
AU7471096A true AU7471096A (en) 1997-05-15
AU706262B2 AU706262B2 (en) 1999-06-10

Family

ID=21717974

Family Applications (1)

Application Number Title Priority Date Filing Date
AU74710/96A Ceased AU706262B2 (en) 1995-10-23 1996-10-23 Compositions and methods for treating bone deficit conditions

Country Status (13)

Country Link
EP (1) EP0866710A4 (en)
JP (1) JP2000513324A (en)
KR (1) KR19990067010A (en)
CN (1) CN1201393A (en)
AU (1) AU706262B2 (en)
BR (1) BR9611210A (en)
CA (1) CA2235481A1 (en)
CZ (1) CZ115398A3 (en)
EA (1) EA199800393A1 (en)
HU (1) HUP9802319A3 (en)
NO (1) NO981810L (en)
PL (1) PL327617A1 (en)
WO (1) WO1997015308A1 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000514048A (en) * 1996-06-20 2000-10-24 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Compounds and methods for providing pharmacologically active preparations and uses thereof
WO1998017267A1 (en) * 1996-10-23 1998-04-30 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US6080779A (en) * 1996-12-13 2000-06-27 Osteoscreen, Inc. Compositions and methods for stimulating bone growth
US6376476B1 (en) 1996-12-13 2002-04-23 Zymogenetics Corporation Isoprenoid pathway inhibitors for stimulating bone growth
WO1999009986A1 (en) * 1997-08-22 1999-03-04 Kyowa Hakko Kogyo Co., Ltd. 4-aminoquinazoline derivatives
US6649631B1 (en) 1997-10-23 2003-11-18 The Board Of Regents Of The University Of Texas System Compositions and methods for treating bone deficit conditions
DE19812204A1 (en) * 1998-03-19 1999-11-04 Plantamed Arzneimittel Gmbh Use of extracts from Cimicifuga racemosa and Belamcanda sinensis as an estrogen-like organ-selective drug without uterotropic effects
JP2000004882A (en) * 1998-06-18 2000-01-11 Hoechst Marion Roussel Kk Human mp52 gene promotor and screening of useful substance using the same
US6838436B1 (en) 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6902721B1 (en) 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
TR200102277T2 (en) * 1998-11-06 2002-01-21 Basf Aktiengesellschaft Ag. Three-ring (Tricyclic) pyrazole derivatives
US6462036B1 (en) 1998-11-06 2002-10-08 Basf Aktiengesellschaft Tricyclic pyrazole derivatives
WO2000078351A1 (en) * 1999-06-18 2000-12-28 Mitsubishi Pharma Corporation Osteogenesis promoters
AU6865100A (en) * 1999-09-02 2001-04-10 Mitsubishi Pharma Corporation Osteogenesis promoting agents
WO2001047891A1 (en) * 1999-12-28 2001-07-05 Eisai Co., Ltd. Heterocyclic compounds having sulfonamide groups
FR2806408B1 (en) * 2000-03-17 2002-10-11 Oreal COSMETIC COMPOSITION COMPRISING A DERIVATIVE OF FURANE- NAPHTOQUINONE, THEIR USE AS COLORING AGENT AND DERIVATIVES
EP1361224B1 (en) 2000-06-05 2005-12-28 Austria Wirtschaftsservice Gesellschaft mit beschränkter Haftung Heterocyclic hydrazones for use as anti-cancer agents
US6660737B2 (en) 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones
US7119120B2 (en) 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
EP1500643A4 (en) * 2002-04-03 2007-03-28 Dainippon Sumitomo Pharma Co Benzamide derivatives
JPWO2004035522A1 (en) * 2002-08-30 2006-02-16 株式会社 ビーエフ研究所 Diagnostic probes and therapeutic agents for prion protein storage diseases and dyes for prion protein
US7118730B2 (en) 2002-12-16 2006-10-10 Bf Research Institute, Inc. Quinoline derivative as diagnostic probe for disease with tau protein accumulation
WO2004069792A2 (en) 2003-02-03 2004-08-19 Janssen Pharmaceutica N.V. Quinoline-derived amide modulators of vanilloid vr1 receptor
AU2005238386A1 (en) 2004-04-30 2005-11-10 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof as an MMP-13 inhibitor
CA2597616A1 (en) 2005-02-17 2006-08-24 Wyeth Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives
PL2118074T3 (en) 2007-02-01 2014-06-30 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular diseases
WO2009076792A1 (en) 2007-12-19 2009-06-25 Givaudan Sa Cooling compounds
ES2532402T3 (en) 2008-06-26 2015-03-26 Resverlogix Corporation Methods of preparing quinazolinone derivatives
ES2542835T3 (en) 2009-01-08 2015-08-12 Resverlogix Corporation Compounds for the prevention and treatment of cardiovascular diseases
US20110319416A1 (en) * 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
EP2408454A2 (en) 2009-03-18 2012-01-25 Resverlogix Corp. Novel anti-inflammatory agents
JP5813626B2 (en) 2009-04-22 2015-11-17 レスバーロジックス コーポレイション New anti-inflammatory agent
KR102011641B1 (en) 2011-11-01 2019-08-19 리스버로직스 코퍼레이션 Oral immediate release formulations for substituted quinazolinones
EP3147280B1 (en) 2012-07-18 2018-03-07 University College Dublin, National University of Ireland, Dublin Anti-angiogenic compound
CN102942515A (en) * 2012-10-22 2013-02-27 暨南大学 Ethane bridged indole compound, synthetic method and application thereof
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
MX2015007921A (en) 2012-12-21 2016-03-03 Zenith Epigenetics Corp Novel heterocyclic compounds as bromodomain inhibitors.
JO3789B1 (en) 2015-03-13 2021-01-31 Resverlogix Corp Compositions and therapeutic methods for the treatment of complement -associated diseases
CN107019687B (en) * 2017-05-08 2020-10-27 上海市伤骨科研究所 Application of N- (4-chlorphenyl) -3-hydroxy-2-naphthamide compound
CN111116552B (en) * 2020-01-17 2022-10-11 河北科技大学 Quinazolinone compound and preparation method thereof
CN114469863B (en) * 2021-11-26 2023-09-26 南方医科大学南方医院 Use of sterol liposomes as drug delivery systems for dental pulp and dentin
CN114288292B (en) * 2021-12-10 2023-06-13 中南大学湘雅医院 Application of aromatic compound as activator of nerve Cong Su protein-B2 in preparation of medicine for treating osteoporosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889851A (en) * 1986-11-21 1989-12-26 Fujisawa Pharmaceutical Co, Ltd. Benzothiadiazine compounds, and pharmaceutical composition comprising the same
JP2724396B2 (en) * 1987-12-18 1998-03-09 武田薬品工業株式会社 Osteoporosis prevention and treatment agent
JPH05508386A (en) * 1989-02-10 1993-11-25 ワシントン　リサーチ　ファンデション immunomodulator
JPH06192272A (en) * 1992-12-24 1994-07-12 Japan Tobacco Inc New triazolobenzothiadiazine and triazolobenzothiadiazepine derivative
US5280040A (en) * 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
EP0716086A1 (en) * 1994-12-09 1996-06-12 Boehringer Mannheim Gmbh Malonic acid based matrix metalloproteinase inhibitors
WO1998017267A1 (en) * 1996-10-23 1998-04-30 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
WO1998025460A1 (en) * 1996-12-13 1998-06-18 Zymogenetics, Inc. Compositions and methods for stimulating bone growth

Also Published As

Publication number Publication date
EP0866710A1 (en) 1998-09-30
HUP9802319A2 (en) 1999-02-01
CA2235481A1 (en) 1997-05-01
NO981810L (en) 1998-06-22
PL327617A1 (en) 1998-12-21
WO1997015308A1 (en) 1997-05-01
CN1201393A (en) 1998-12-09
EA199800393A1 (en) 1998-12-24
AU706262B2 (en) 1999-06-10
CZ115398A3 (en) 1998-12-16
EP0866710A4 (en) 2001-07-11
BR9611210A (en) 1999-12-28
HUP9802319A3 (en) 1999-12-28
NO981810D0 (en) 1998-04-22
KR19990067010A (en) 1999-08-16
JP2000513324A (en) 2000-10-10

Similar Documents

Publication Publication Date Title
AU7471096A (en) Compositions and methods for treating bone deficit conditions
AU4988997A (en) Compositions and methods for treating bone deficit conditions
AU5439996A (en) Compositions and methods for treating pain
ZA963844B (en) Seed treatment composition and method
AU5668796A (en) Dermatological-wound healing compositions and methods for pr eparing and using same
AU2113295A (en) Novel compositions and methods for water treatment
AU1128297A (en) Composition for treating pain
AU4778096A (en) Bone graft composition
AU1831597A (en) Methods and compositions for inhibiting hexokinase
AU5387796A (en) Method and compositions for treating impotence
AU5855796A (en) Methods for inhibiting bone loss
AU1987795A (en) Guided bone rasp
AU5499896A (en) Hair treatment compositions
AU4655296A (en) Compositions and methods for treating tumor cells
AU3512295A (en) Composition and method for treating hair
AU5081298A (en) Surgical method and composition therefor
AU9214398A (en) Compositions and methods for treating water
AU2327599A (en) Compositions and methods for treating autoimmune diseases
AU1714697A (en) Method and composition for the treatment of osteoarthritis
AU3369595A (en) Methods for inhibiting bone prosthesis degeneration
AU3768795A (en) Method and compositions for hair treatment
AU5594398A (en) Methods and compositions for preventing and treating bone loss
AU5631096A (en) Antihistamine-wound healing compositions and methods for pre paring and using same
AU5743396A (en) Methods for inhibiting bone loss
AU4695296A (en) Compositions and methods for treating rheumatoid arthritis